Addex Therapeutics Ltd (ADXN)
8.79
-0.21
(-2.33%)
USD |
NASDAQ |
May 16, 16:00
8.77
-0.02
(-0.23%)
After-Hours: 20:00
Addex Therapeutics Cash from Operations (Quarterly): -0.5563M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.5563M |
| September 30, 2023 | -2.651M |
| June 30, 2023 | -3.146M |
| March 31, 2023 | -2.548M |
| December 31, 2022 | -3.396M |
| September 30, 2022 | -2.777M |
| June 30, 2022 | -5.816M |
| March 31, 2022 | -5.245M |
| December 31, 2021 | -3.279M |
| September 30, 2021 | -2.685M |
| Date | Value |
|---|---|
| June 30, 2021 | -7.064M |
| March 31, 2021 | -3.061M |
| December 31, 2020 | 1.020M |
| September 30, 2020 | -3.296M |
| June 30, 2020 | -6.416M |
| March 31, 2020 | -4.300M |
| December 31, 2019 | 0.1026M |
| September 30, 2019 | -5.044M |
| June 30, 2019 | -2.046M |
| March 31, 2019 | -2.557M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-7.064M
Minimum
Jun 2021
1.020M
Maximum
Dec 2020
-3.274M
Average
-3.146M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| AC Immune SA | 1.172M |
| CRISPR Therapeutics AG | 109.75M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -17.00M |
| MoonLake Immunotherapeutics | -14.95M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.0012M |
| Cash from Financing (Quarterly) | -0.1643M |
| Free Cash Flow | -8.908M |
| Free Cash Flow Per Share (Quarterly) | -0.775 |
| Free Cash Flow to Equity (Quarterly) | -0.5575M |
| Free Cash Flow to Firm (Quarterly) | -0.5575M |
| Free Cash Flow Yield | -163.8% |